RTS,S AS01, a recombinant protein candidate malaria vaccine that targets the P. falciparum CSP is the first to reach phase three clinical testing and is partially effective against clinical disease in young African children up to 4 years after vaccination, according to final trial data [30]. Here, DNAJC5 is linked to malaria.